CARs are engineered targeting molecules comprised of a tumour-specific antibody linked to a T cell activating receptor
. T cells engineered to express CARs (CAR-T cells) are capable of mounting specific and highly effective immune responses against tumours.
Given that decreased proportions of activating receptor expressing NK cells were observed in the peripheral blood of GC patients, we measured the plasma concentration of TGF-[beta]1 in GC patients.
The engagement of activating receptors such as NKG2D, DNAM-1, and the natural cytotoxicity receptors NKp30, NKp44, and NKp46 is still required for the robust activation of NK cells and NK cell-mediated killing of transformed cancer cells [8, 9].
Sanofi and Innate Pharma entered a research collaboration and licensing agreement to apply Innate Pharma's new proprietary technology to the development of innovative bispecific antibody formats engaging natural killer (NK) cells to kill tumor cells through the activating receptor
Jung, "Regulation of ligands for the NKG2D activating receptor
," Annual Review of Immunology, vol.
Celyad's lead candidate, NKR-2, is a T-Cell engineered to express the human NK receptor, NKG2D, which is an activating receptor
that triggers cell killing through the binding of NKG2D to any of eight naturally occurring ligands that are known to be overexpressed on more than 80% of tumours.
The m157 glycoprotein, specifically expressed by MCMV-infected cells, is recognized by the Ly49H activating receptor
expressed on a murine NK cell subset [38, 55] and is able to induce a selective activation and expansion of [Ly49H.sup.+] NK cell subset .
The group's previous research has shown that intake of US produced, Montmorency tartcherries activates PPAR isoforms (peroxisome proliferator activating receptors
) in many of the body's tissues.
The triggering receptors expressed on myeloid cells (TREM) are a family of activating receptors
that participate in diverse cell processes, including inflammation, bone homeostasis, neurological development and coagulation.
Tony Lam at the Toronto General Research Institute and the University of Toronto discovered that activating receptors
of the cholecystokinin (CCK) peptide hormone in the gut rapidly and potently lowers blood glucose levels by triggering a signal to the brain and then to the liver to lower glucose or sugar production.